Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
January 24 2023 - 8:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercializing non-invasive wearable sensors and supporting
personalized lifestyle and weight reduction programs, announces
initial results from patient studies of its metabolic health
program Miboko with the National Health Service (NHS) in the United
Kingdom.
The initial pilot program recruited 30
individuals that were classified as obese according to their BMI.
The first cohort of 10 patients have been enrolled in the program
for over 12 weeks. Results from this cohort indicate that these
individuals achieved an average weight loss of 3.7 pounds and an
average BMI improvement of 0.6 after 10 weeks, with 100% of
participants achieving some weight improvement. This level of
average weight loss exceeds some of the publicly reported results
in studies of other weight loss programs. As the Miboko program is
optimized, average weight loss is expected to increase. The program
is designed to continue for at least one year, with new patients
being enrolled each month.
Feedback from participants shows that use of the
body-worn sensor led to greater engagement and an element of
gamification that is anticipated to lead to sustained use and
encourage incremental dietary and lifestyle changes through a
combination of personalized data and targeted education modules.
Participants expressed their willingness to continue with the
program, reporting that they do not see Miboko as a traditional
diet plan, which the Company expects will avoid diet fatigue and
drop-off rates widely associated with many of the current weight
loss programs.
“These results are incredibly encouraging, as
they validate the approach that we developed some time ago that
integrates the use of a non-invasive glucose sensor with
personalized, app-driven coaching and analytics,” commented Faz
Chowdhury, Ph.D., CEO of Nemaura Medical. “We look forward to
continuing the study with the National Health Service and
anticipate seeing increasingly robust findings as we continue to
follow these users and initiate new users each month.”
The Miboko program is the first to integrate a
daily-wear non-invasive glucose sensor with a lifestyle app, which
includes recording of food and drink, educational content, and an
analytics platform. The wellness program provides each user a
metabolic score based on diet, exercise, and glucose response to
food intake, which is determined by the sensor. Users are given
personalized recommendations to help them lose weight, potentially
avoid chronic health issues , and enjoy a better quality of
life.
As studies continue, lessons learned will be
used to improve and introduce new features into the program. The
integration of Nemaura’s daily-wear non-invasive glucose sensor is
a unique feature that is unavailable in any other plan, and the
Company is now evaluating options to provide the core part of the
program and glucose sensors as add-ons to existing diet and
metabolic health programs globally.
The Company expects the UK National Health
Service will publish detailed study results following further
analysis.
About
MibokoMiboko integrates Nemaura’s non-invasive
sensor with a diet and wellbeing program to provide an indication
of a person’s metabolic health and wellbeing. The partnership with
the UK’s NHS is through medical centers that are partnered with the
NHS’s National Institute for Health and Care Research (NIHR) to
gather information that helps change and save lives. The Practice
where the studies are being undertaken are certified Research Ready
by the Royal College of General Practitioners and regularly
undertakes independent studies.
Miboko will be initially available without
prescription and is recommended for use by those wishing to lose
weight and improve their general health and wellbeing. The program
will be relevant to those with prediabetes as well as to people
with obesity. Significantly, Miboko will also be used by people who
wish to embark on a diet program, many of whom will have tried
alternative diet plans. The Company has plans to gather long-term
outcome data that could potentially support reimbursement.
About Nemaura
Medical, Inc.Nemaura Medical Inc. is a medical
technology company developing and commercialising noninvasive
wearable diagnostic devices. The company is currently also
commercialising sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark
approved Class IIb medical device, as a non-invasive and flexible
continuous glucose monitor (CGM) providing actionable insights
derived from real time glucose measurements and daily glucose trend
data, which may help people with diabetes and prediabetes to better
manage, reverse, and prevent the onset of diabetes. Nemaura has
submitted a PMA (Premarket Approval Application) for sugarBEAT® to
the U.S. FDA. proBEAT™ combines non-invasive glucose data processed
using artificial intelligence under a digital healthcare
subscription service that has been piloted in the U.S. as a general
wellness product as part of its BEAT® diabetes program.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the U.S., risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The U.S.
Food and Drug Administration (the “FDA”) reserves the right to
re-evaluate its decision that proBEAT™ qualifies as a general
wellness product should it become aware of any issues such as skin
irritation or other adverse events from the device, as well as any
misuse impacting patient safety, and any other reason as the FDA
may see fit at its discretion to determine the product does not fit
the definition of a general wellness product. There can be no
assurance that the KSA will approve the registration for
sugarBEAT® in Saudi Arabia.These and other risks and
uncertainties are identified and described in more detail in
Nemaura’s filings with the United States Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the most recently completed fiscal year, its
Quarterly Reports on Form 10-Q, and its Current Reports on Form
8-K. Nemaura undertakes no obligation to publicly update or revise
any forward-looking statements.
For more information, please visit www.NemauraMedical.com.
MEDIA CONTACT
CORE IRJules Abraham+1 917-885-7378
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024